PubMed:10101034
Annnotations
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-174 | Sentence | denotes | Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. |
| T2 | 175-275 | Sentence | denotes | The therapeutic potential of drugs that block the induction of cyclooxygenase-2 has been emphasized. |
| T3 | 276-788 | Sentence | denotes | When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and >10 mM, respectively). |
| T4 | 789-857 | Sentence | denotes | However, only triflusal and aspirin inhibited purified COX-2 enzyme. |
| T5 | 858-1077 | Sentence | denotes | To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent inhibition of COX-2 protein expression in peripheral human mononuclear cells. |
| T6 | 1078-1334 | Sentence | denotes | This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression. |
| T7 | 1335-1553 | Sentence | denotes | This different behavior may be, at least in part, due to the ability of HTB and triflusal to block the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate. |
| T8 | 1554-1763 | Sentence | denotes | Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis. |
| T9 | 1764-1990 | Sentence | denotes | Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated. |
| T1 | 0-174 | Sentence | denotes | Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. |
| T2 | 175-275 | Sentence | denotes | The therapeutic potential of drugs that block the induction of cyclooxygenase-2 has been emphasized. |
| T3 | 276-788 | Sentence | denotes | When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and >10 mM, respectively). |
| T4 | 789-857 | Sentence | denotes | However, only triflusal and aspirin inhibited purified COX-2 enzyme. |
| T5 | 858-1077 | Sentence | denotes | To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent inhibition of COX-2 protein expression in peripheral human mononuclear cells. |
| T6 | 1078-1334 | Sentence | denotes | This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression. |
| T7 | 1335-1553 | Sentence | denotes | This different behavior may be, at least in part, due to the ability of HTB and triflusal to block the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate. |
| T8 | 1554-1763 | Sentence | denotes | Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis. |
| T9 | 1764-1990 | Sentence | denotes | Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated. |
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 14-30 | protein | denotes | cyclooxygenase-2 |
| T2 | 238-254 | protein | denotes | cyclooxygenase-2 |
| T3 | 511-527 | protein | denotes | cyclooxygenase-2 |
| T4 | 835-856 | protein | denotes | purified COX-2 enzyme |
| T5 | 1014-1019 | protein | denotes | COX-2 |
| T6 | 1042-1076 | cell_type | denotes | peripheral human mononuclear cells |
| T7 | 1317-1322 | protein | denotes | COX-2 |
| T8 | 1477-1498 | protein | denotes | nuclear factor-kappaB |
| T9 | 1841-1846 | protein | denotes | COX-2 |
| T10 | 1943-1964 | protein | denotes | nuclear factor-kappaB |
semrep-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| E1-ti-1 | 14-30 | cui:C0387583 | denotes | cyclooxygenase-2 |
| E2-ti-1 | 31-41 | cui:C0185117 | denotes | expression |
| E3-ti-1 | 63-74 | cui:C0243072 | denotes | derivatives |
| E4-ti-1 | 78-88 | cui:C0036075 | denotes | salicylate |
| E5-ti-1 | 90-99 | cui:C0077126 | denotes | triflusal |
| E6-ti-1 | 122-132 | cui:C0870883 | denotes | metabolite |
| E7-ti-1 | 134-173 | cui:C0048733 | denotes | 2-hydroxy-4-trifluoromethylbenzoic acid |
| T1 | 0-10 | INHIBITS | denotes | Inhibition |
| E1-ab-1 | 179-190 | cui:C0302350 | denotes | therapeutic |
| E2-ab-1 | 191-200 | cui:C0237399 | denotes | potential |
| E3-ab-1 | 204-209 | cui:C0013227 | denotes | drugs |
| E4-ab-1 | 225-234 | cui:C0857127 | denotes | induction |
| E5-ab-1 | 238-254 | cui:C0387583 | denotes | cyclooxygenase-2 |
| E1-ab-2 | 281-284 | cui:C0205448 | denotes | two |
| E2-ab-2 | 303-313 | cui:C0036075 | denotes | salicylate |
| E3-ab-2 | 314-325 | cui:C0243072 | denotes | derivatives |
| E4-ab-2 | 355-367 | cui:C0053225 | denotes | benzoic acid |
| E5-ab-2 | 369-378 | cui:C0077126 | denotes | triflusal |
| E6-ab-2 | 401-411 | cui:C0870883 | denotes | metabolite |
| E7-ab-2 | 414-451 | cui:C0020317 | denotes | hydroxy-4-trifluoromethylbenzoic acid |
| E8-ab-2 | 478-485 | cui:C0004057 | denotes | aspirin |
| E9-ab-2 | 490-507 | cui:C0037549 | denotes | sodium salicylate |
| E10-ab-2 | 511-546 | cui:C1257954 | denotes | cyclooxygenase-2 (COX-2) inhibitors |
| E11-ab-2 | 568-577 | cui:C0521009 | denotes | bacterial |
| E12-ab-2 | 578-596 | cui:C0023810 | denotes | lipopolysaccharide |
| E13-ab-2 | 597-606 | cui:C1515877 | denotes | activated |
| E14-ab-2 | 607-612 | cui:C0020114 | denotes | human |
| E15-ab-2 | 613-618 | cui:C0005767 | denotes | blood |
| E16-ab-2 | 620-629 | cui:C0077126 | denotes | triflusal |
| E17-ab-2 | 631-638 | cui:C0004057 | denotes | aspirin |
| E18-ab-2 | 644-647 | cui:C0020317 | denotes | HTB |
| E19-ab-2 | 653-656 | cui:C1518422 | denotes | not |
| E20-ab-2 | 657-674 | cui:C0037549 | denotes | sodium salicylate |
| E21-ab-2 | 686-691 | cui:C0387583 | denotes | COX-2 |
| E22-ab-2 | 692-700 | cui:C0086597 | denotes | mediated |
| E23-ab-2 | 701-735 | cui:C1514503 | denotes | prostaglandin E2 (PGE2) production |
| E24-ab-2 | 737-741 | cui:C0600495 | denotes | IC50 |
| T2 | 464-472 | compared_with | denotes | compared |
| T3 | 355-378 | ISA | denotes | benzoic acid (triflusal |
| T4 | 355-378 | ISA | denotes | benzoic acid (triflusal |
| T5 | 355-378 | ISA | denotes | benzoic acid (triflusal |
| T6 | 565-567 | LOCATION_OF | denotes | in |
| T7 | 676-685 | DISRUPTS | denotes | inhibited |
| T8 | 676-685 | DISRUPTS | denotes | inhibited |
| T9 | 355-378 | compared_with | denotes | benzoic acid (triflusal |
| E1-ab-3 | 803-812 | cui:C0077126 | denotes | triflusal |
| E2-ab-3 | 817-824 | cui:C0004057 | denotes | aspirin |
| E3-ab-3 | 844-849 | cui:C0387583 | denotes | COX-2 |
| E4-ab-3 | 850-856 | cui:C0014442 | denotes | enzyme |
| T10 | 825-834 | INHIBITS | denotes | inhibited |
| T11 | 825-834 | INHIBITS | denotes | inhibited |
| E1-ab-4 | 871-879 | cui:C0750489 | denotes | apparent |
| E2-ab-4 | 880-891 | cui:C1290905 | denotes | discrepancy |
| E3-ab-4 | 910-913 | cui:C0020317 | denotes | HTB |
| E4-ab-4 | 918-927 | cui:C0077126 | denotes | triflusal |
| E5-ab-4 | 941-948 | cui:C0004057 | denotes | aspirin |
| E6-ab-4 | 953-963 | cui:C0036075 | denotes | salicylate |
| E7-ab-4 | 1014-1019 | cui:C0387583 | denotes | COX-2 |
| E8-ab-4 | 1020-1038 | cui:C1171362 | denotes | protein expression |
| E9-ab-4 | 1042-1052 | cui:C0205100 | denotes | peripheral |
| E10-ab-4 | 1053-1058 | cui:C0020114 | denotes | human |
| E11-ab-4 | 1059-1076 | cui:C0806987 | denotes | mononuclear cells |
| T12 | 1053-1076 | PART_OF | denotes | human mononuclear cells |
| T13 | 1039-1041 | LOCATION_OF | denotes | in |
| E1-ab-5 | 1099-1106 | cui:C1517331 | denotes | further |
| E2-ab-5 | 1122-1125 | cui:C0034693 | denotes | rat |
| E3-ab-5 | 1126-1129 | cui:C0001861 | denotes | air |
| E4-ab-5 | 1136-1141 | cui:C0026336 | denotes | model |
| E5-ab-5 | 1165-1172 | cui:C0004057 | denotes | aspirin |
| E6-ab-5 | 1177-1186 | cui:C0077126 | denotes | triflusal |
| E7-ab-5 | 1197-1212 | cui:C1514503 | denotes | PGE2 production |
| E8-ab-5 | 1270-1279 | cui:C0077126 | denotes | triflusal |
| E9-ab-5 | 1280-1287 | cui:C1522326 | denotes | treated |
| E10-ab-5 | 1288-1295 | cui:C0003062 | denotes | animals |
| E11-ab-5 | 1305-1313 | cui:C0547047 | denotes | decrease |
| E12-ab-5 | 1317-1322 | cui:C0387583 | denotes | COX-2 |
| E13-ab-5 | 1323-1333 | cui:C0185117 | denotes | expression |
| T14 | 1187-1196 | DISRUPTS | denotes | inhibited |
| T15 | 1187-1196 | DISRUPTS | denotes | inhibited |
| E1-ab-6 | 1340-1349 | cui:C1547020 | denotes | different |
| E2-ab-6 | 1350-1358 | cui:C0004927 | denotes | behavior |
| E3-ab-6 | 1379-1383 | cui:C0449719 | denotes | part |
| E4-ab-6 | 1396-1403 | cui:C0085732 | denotes | ability |
| E5-ab-6 | 1407-1410 | cui:C0020317 | denotes | HTB |
| E6-ab-6 | 1415-1424 | cui:C0077126 | denotes | triflusal |
| E7-ab-6 | 1456-1476 | cui:C0040648 | denotes | transcription factor |
| E8-ab-6 | 1477-1484 | cui:C0521447 | denotes | nuclear |
| E9-ab-6 | 1504-1510 | cui:C0205250 | denotes | higher |
| E10-ab-6 | 1511-1517 | cui:C0439792 | denotes | extent |
| E11-ab-6 | 1523-1530 | cui:C0004057 | denotes | aspirin |
| E12-ab-6 | 1535-1552 | cui:C0037549 | denotes | sodium salicylate |
| E1-ab-7 | 1563-1571 | cui:C0442796 | denotes | addition |
| E2-ab-7 | 1575-1585 | cui:C0311403 | denotes | inhibiting |
| E3-ab-7 | 1590-1595 | cui:C0387583 | denotes | COX-2 |
| E4-ab-7 | 1596-1604 | cui:C0439167 | denotes | activity |
| E5-ab-7 | 1608-1619 | cui:C0302350 | denotes | therapeutic |
| E6-ab-7 | 1620-1634 | cui:C0086045 | denotes | concentrations |
| E7-ab-7 | 1636-1645 | cui:C0077126 | denotes | triflusal |
| E8-ab-7 | 1649-1653 | cui:C1299581 | denotes | able |
| E9-ab-7 | 1675-1685 | cui:C0870883 | denotes | metabolite |
| E10-ab-7 | 1686-1689 | cui:C0020317 | denotes | HTB |
| E11-ab-7 | 1694-1704 | cui:C0185117 | denotes | expression |
| E12-ab-7 | 1708-1711 | cui:C0205314 | denotes | new |
| E13-ab-7 | 1712-1718 | cui:C0014442 | denotes | enzyme |
| E14-ab-7 | 1748-1752 | cui:C0012472 | denotes | PGE2 |
| E15-ab-7 | 1753-1762 | cui:C0869032 | denotes | synthesis |
| T16 | 1636-1689 | ISA | denotes | triflusal is able to block through its metabolite HTB |
| T17 | 1657-1662 | INHIBITS | denotes | block |
| T18 | 1636-1689 | INHIBITS | denotes | triflusal is able to block through its metabolite HTB |
| E1-ab-8 | 1764-1773 | cui:C0077126 | denotes | Triflusal |
| E2-ab-8 | 1778-1781 | cui:C0020317 | denotes | HTB |
| E3-ab-8 | 1803-1810 | cui:C1280500 | denotes | effects |
| E4-ab-8 | 1814-1823 | cui:C1522240 | denotes | processes |
| E5-ab-8 | 1833-1840 | cui:C1515568 | denotes | de novo |
| E6-ab-8 | 1841-1846 | cui:C0387583 | denotes | COX-2 |
| E7-ab-8 | 1847-1857 | cui:C0185117 | denotes | expression |
| E8-ab-8 | 1880-1887 | cui:C0332464 | denotes | broader |
| E9-ab-8 | 1898-1910 | cui:C1521733 | denotes | pathological |
| E10-ab-8 | 1931-1936 | cui:C0017337 | denotes | genes |
| E11-ab-8 | 1943-1950 | cui:C0521447 | denotes | nuclear |
| E12-ab-8 | 1951-1957 | cui:C1521761 | denotes | factor |
| E13-ab-8 | 1965-1972 | cui:C0243148 | denotes | control |
| T19 | 1824-1826 | COEXISTS_WITH | denotes | in |
| T20 | 1824-1826 | COEXISTS_WITH | denotes | in |
| R1 | E4-ti-1 | T1 | subjectOf | salicylate,Inhibition |
| R2 | E1-ti-1 | T1 | objectOf | cyclooxygenase-2,Inhibition |
| R3 | E7-ab-2 | T2 | subjectOf | hydroxy-4-trifluoromethylbenzoic acid,compared |
| R4 | E8-ab-2 | T2 | objectOf | aspirin,compared |
| R5 | E5-ab-2 | T3 | subjectOf | triflusal,benzoic acid (triflusal |
| R6 | E4-ab-2 | T3 | objectOf | benzoic acid,benzoic acid (triflusal |
| R7 | E5-ab-2 | T4 | subjectOf | triflusal,benzoic acid (triflusal |
| R8 | E18-ab-2 | T4 | objectOf | HTB,benzoic acid (triflusal |
| R9 | E5-ab-2 | T5 | subjectOf | triflusal,benzoic acid (triflusal |
| R10 | E7-ab-2 | T5 | objectOf | hydroxy-4-trifluoromethylbenzoic acid,benzoic acid (triflusal |
| R11 | E15-ab-2 | T6 | subjectOf | blood,in |
| R12 | E10-ab-2 | T6 | objectOf | cyclooxygenase-2 (COX-2) inhibitors,in |
| R13 | E20-ab-2 | T7 | subjectOf | sodium salicylate,inhibited |
| R14 | E23-ab-2 | T7 | objectOf | prostaglandin E2 (PGE2) production,inhibited |
| R15 | E9-ab-2 | T8 | subjectOf | sodium salicylate,inhibited |
| R16 | E23-ab-2 | T8 | objectOf | prostaglandin E2 (PGE2) production,inhibited |
| R17 | E5-ab-2 | T9 | subjectOf | triflusal,benzoic acid (triflusal |
| R18 | E8-ab-2 | T9 | objectOf | aspirin,benzoic acid (triflusal |
| R19 | E2-ab-3 | T10 | subjectOf | aspirin,inhibited |
| R20 | E3-ab-3 | T10 | objectOf | COX-2,inhibited |
| R21 | E1-ab-3 | T11 | subjectOf | triflusal,inhibited |
| R22 | E3-ab-3 | T11 | objectOf | COX-2,inhibited |
| R23 | E11-ab-4 | T12 | subjectOf | mononuclear cells,human mononuclear cells |
| R24 | E10-ab-4 | T12 | objectOf | human,human mononuclear cells |
| R25 | E11-ab-4 | T13 | subjectOf | mononuclear cells,in |
| R26 | E7-ab-4 | T13 | objectOf | COX-2,in |
| R27 | E6-ab-5 | T14 | subjectOf | triflusal,inhibited |
| R28 | E7-ab-5 | T14 | objectOf | PGE2 production,inhibited |
| R29 | E5-ab-5 | T15 | subjectOf | aspirin,inhibited |
| R30 | E7-ab-5 | T15 | objectOf | PGE2 production,inhibited |
| R31 | E7-ab-7 | T16 | subjectOf | triflusal,triflusal is able to block through its metabolite HTB |
| R32 | E10-ab-7 | T16 | objectOf | HTB,triflusal is able to block through its metabolite HTB |
| R33 | E7-ab-7 | T17 | subjectOf | triflusal,block |
| R34 | E10-ab-7 | T17 | objectOf | HTB,block |
| R35 | E7-ab-7 | T18 | subjectOf | triflusal,triflusal is able to block through its metabolite HTB |
| R36 | E7-ab-7 | T18 | objectOf | triflusal,triflusal is able to block through its metabolite HTB |
| R37 | E2-ab-8 | T19 | subjectOf | HTB,in |
| R38 | E6-ab-8 | T19 | objectOf | COX-2,in |
| R39 | E1-ab-8 | T20 | subjectOf | Triflusal,in |
| R40 | E6-ab-8 | T20 | objectOf | COX-2,in |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-174 | Sentence | denotes | Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid. |
| S2 | 175-275 | Sentence | denotes | The therapeutic potential of drugs that block the induction of cyclooxygenase-2 has been emphasized. |
| S3 | 276-788 | Sentence | denotes | When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-trifluoromethyl-benzoic acid (triflusal) and its deacetylated metabolite 2-hydroxy-4-trifluoromethylbenzoic acid (HTB)] were compared with aspirin and sodium salicylate as cyclooxygenase-2 (COX-2) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-mediated prostaglandin E2 (PGE2) production (IC50 = 0.16, 0.18, 0.39, and >10 mM, respectively). |
| S4 | 789-857 | Sentence | denotes | However, only triflusal and aspirin inhibited purified COX-2 enzyme. |
| S5 | 858-1077 | Sentence | denotes | To test this apparent discrepancy, we realized that HTB and triflusal (but neither aspirin nor salicylate) produced a concentration-dependent inhibition of COX-2 protein expression in peripheral human mononuclear cells. |
| S6 | 1078-1334 | Sentence | denotes | This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production (ID50 = 18.9 and 11.4 mg/kg p.o., respectively) but only triflusal-treated animals showed a decrease in COX-2 expression. |
| S7 | 1335-1553 | Sentence | denotes | This different behavior may be, at least in part, due to the ability of HTB and triflusal to block the activation of the transcription factor nuclear factor-kappaB to a higher extent than aspirin and sodium salicylate. |
| S8 | 1554-1763 | Sentence | denotes | Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis. |
| S9 | 1764-1990 | Sentence | denotes | Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under nuclear factor-kappaB control are up-regulated. |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 90-99 | NP | denotes | triflusal |
| C3 | 105-108 | NP | denotes | its |
| C2 | 105-132 | NP | denotes | its deacetylated metabolite |
| C4 | 134-173 | NP | denotes | 2-hydroxy-4-trifluoromethylbenzoic acid |
| C5 | 204-209 | NP | denotes | drugs |
| C6 | 210-214 | NP | denotes | that |
| C7 | 238-254 | NP | denotes | cyclooxygenase-2 |
| C8 | 620-629 | NP | denotes | triflusal |
| C9 | 631-638 | NP | denotes | aspirin |
| C10 | 644-647 | NP | denotes | HTB |
| C11 | 657-674 | NP | denotes | sodium salicylate |
| C12 | 798-824 | NP | denotes | only triflusal and aspirin |
| C14 | 910-913 | NP | denotes | HTB |
| C15 | 918-927 | NP | denotes | triflusal |
| C13 | 910-927 | NP | denotes | HTB and triflusal |
| C16 | 1014-1038 | NP | denotes | COX-2 protein expression |
| C17 | 1120-1149 | NP | denotes | a rat air pouch model in vivo |
| C18 | 1154-1159 | NP | denotes | which |
| C19 | 1160-1186 | NP | denotes | both aspirin and triflusal |
| C20 | 1317-1333 | NP | denotes | COX-2 expression |
| C22 | 1407-1410 | NP | denotes | HTB |
| C23 | 1415-1424 | NP | denotes | triflusal |
| C21 | 1407-1424 | NP | denotes | HTB and triflusal |
| C24 | 1523-1530 | NP | denotes | aspirin |
| C25 | 1535-1552 | NP | denotes | sodium salicylate |
| C26 | 1636-1645 | NP | denotes | triflusal |
| C28 | 1671-1674 | NP | denotes | its |
| C27 | 1671-1689 | NP | denotes | its metabolite HTB |
| C30 | 1764-1773 | NP | denotes | Triflusal |
| C31 | 1778-1781 | NP | denotes | HTB |
| C29 | 1764-1781 | NP | denotes | Triflusal and HTB |
| C32 | 1814-1823 | NP | denotes | processes |
| C33 | 1827-1832 | NP | denotes | which |
| C34 | 1898-1921 | NP | denotes | pathological situations |
| C35 | 1925-1930 | NP | denotes | which |
| R1 | C3 | C7 | coref-pron | its,cyclooxygenase-2 |
| R2 | C4 | C2 | coref-appos | 2-hydroxy-4-trifluoromethylbenzoic acid,its deacetylated metabolite |
| R3 | C6 | C5 | coref-relat | that,drugs |
| R4 | C8 | C1 | coref-ident | triflusal,triflusal |
| R5 | C10 | C2 | coref-ident | HTB,its deacetylated metabolite |
| R6 | C14 | C10 | coref-ident | HTB,HTB |
| R7 | C15 | C8 | coref-ident | triflusal,triflusal |
| R8 | C18 | C17 | coref-relat | which,a rat air pouch model in vivo |
| R9 | C19 | C12 | coref-ident | both aspirin and triflusal,only triflusal and aspirin |
| R10 | C20 | C16 | coref-ident | COX-2 expression,COX-2 protein expression |
| R11 | C22 | C14 | coref-ident | HTB,HTB |
| R12 | C23 | C15 | coref-ident | triflusal,triflusal |
| R13 | C21 | C13 | coref-ident | HTB and triflusal,HTB and triflusal |
| R14 | C24 | C9 | coref-ident | aspirin,aspirin |
| R15 | C25 | C11 | coref-ident | sodium salicylate,sodium salicylate |
| R16 | C26 | C23 | coref-ident | triflusal,triflusal |
| R17 | C28 | C7 | coref-pron | its,cyclooxygenase-2 |
| R18 | C27 | C22 | coref-ident | its metabolite HTB,HTB |
| R19 | C30 | C26 | coref-ident | Triflusal,triflusal |
| R20 | C31 | C27 | coref-ident | HTB,its metabolite HTB |
| R21 | C29 | C21 | coref-ident | Triflusal and HTB,HTB and triflusal |
| R22 | C33 | C32 | coref-relat | which,processes |
| R23 | C35 | C34 | coref-relat | which,pathological situations |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 14-30 | protein_molecule | denotes | cyclooxygenase-2 |
| T2 | 45-74 | other_organic_compound | denotes | 4-trifluoromethyl derivatives |
| T3 | 78-88 | other_organic_compound | denotes | salicylate |
| T4 | 90-99 | other_organic_compound | denotes | triflusal |
| T5 | 109-132 | other_organic_compound | denotes | deacetylated metabolite |
| T6 | 134-173 | other_organic_compound | denotes | 2-hydroxy-4-trifluoromethylbenzoic acid |
| T7 | 238-254 | protein_molecule | denotes | cyclooxygenase-2 |
| T8 | 285-325 | other_organic_compound | denotes | 4-trifluoromethyl salicylate derivatives |
| T9 | 327-367 | other_organic_compound | denotes | 2-acetoxy-4-trifluoromethyl-benzoic acid |
| T10 | 369-378 | other_organic_compound | denotes | triflusal |
| T11 | 388-411 | other_organic_compound | denotes | deacetylated metabolite |
| T12 | 412-451 | other_organic_compound | denotes | 2-hydroxy-4-trifluoromethylbenzoic acid |
| T13 | 453-456 | other_organic_compound | denotes | HTB |
| T14 | 511-527 | protein_molecule | denotes | cyclooxygenase-2 |
| T15 | 568-618 | tissue | denotes | bacterial lipopolysaccharide-activated human blood |
| T16 | 620-629 | other_organic_compound | denotes | triflusal |
| T17 | 631-638 | other_organic_compound | denotes | aspirin |
| T18 | 644-647 | other_organic_compound | denotes | HTB |
| T19 | 657-674 | other_organic_compound | denotes | sodium salicylate |
| T20 | 686-717 | other_organic_compound | denotes | COX-2-mediated prostaglandin E2 |
| T21 | 719-723 | other_organic_compound | denotes | PGE2 |
| T22 | 803-812 | other_organic_compound | denotes | triflusal |
| T23 | 817-824 | other_organic_compound | denotes | aspirin |
| T24 | 835-856 | protein_molecule | denotes | purified COX-2 enzyme |
| T25 | 910-913 | other_organic_compound | denotes | HTB |
| T26 | 918-927 | other_organic_compound | denotes | triflusal |
| T27 | 941-948 | other_organic_compound | denotes | aspirin |
| T28 | 953-963 | other_organic_compound | denotes | salicylate |
| T29 | 1014-1019 | protein_molecule | denotes | COX-2 |
| T30 | 1042-1076 | cell_type | denotes | peripheral human mononuclear cells |
| T31 | 1122-1141 | other_name | denotes | rat air pouch model |
| T32 | 1165-1172 | other_organic_compound | denotes | aspirin |
| T33 | 1177-1186 | other_organic_compound | denotes | triflusal |
| T34 | 1197-1201 | other_organic_compound | denotes | PGE2 |
| T35 | 1270-1279 | other_organic_compound | denotes | triflusal |
| T36 | 1317-1322 | protein_molecule | denotes | COX-2 |
| T37 | 1407-1410 | other_organic_compound | denotes | HTB |
| T38 | 1415-1424 | other_organic_compound | denotes | triflusal |
| T39 | 1477-1498 | protein_complex | denotes | nuclear factor-kappaB |
| T40 | 1523-1530 | other_organic_compound | denotes | aspirin |
| T41 | 1535-1552 | other_organic_compound | denotes | sodium salicylate |
| T42 | 1590-1604 | other_name | denotes | COX-2 activity |
| T43 | 1636-1645 | other_organic_compound | denotes | triflusal |
| T44 | 1686-1689 | other_organic_compound | denotes | HTB |
| T45 | 1748-1752 | other_organic_compound | denotes | PGE2 |
| T46 | 1764-1773 | other_organic_compound | denotes | Triflusal |
| T47 | 1778-1781 | other_organic_compound | denotes | HTB |
| T48 | 1841-1846 | protein_molecule | denotes | COX-2 |
| T49 | 1943-1964 | protein_complex | denotes | nuclear factor-kappaB |
metamap-sample
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 1842-1847 | C0387583 | denotes | OX-2 |
| T2 | 1591-1596 | C0387583 | denotes | OX-2 |
| T3 | 1015-1020 | C0387583 | denotes | OX-2 |
| T4 | 845-850 | C0387583 | denotes | OX-2 |
| T5 | 687-692 | C0387583 | denotes | OX-2- |
| T6 | 239-254 | C0387583 | denotes | yclooxygenase-2 |
| T7 | 15-31 | C0387583 | denotes | yclooxygenase-2 |
| T8 | 135-174 | C0048733 | denotes | -hydroxy-4-trifluoromethylbenzoic acid. |
| T9 | 1765-1774 | C0077126 | denotes | riflusal |
| T10 | 1637-1646 | C0077126 | denotes | riflusal |
| T11 | 1416-1425 | C0077126 | denotes | riflusal |
| T12 | 919-928 | C0077126 | denotes | riflusal |
| T13 | 804-813 | C0077126 | denotes | riflusal |
| T14 | 328-368 | C0077126 | denotes | -acetoxy-4-trifluoromethyl-benzoic acid |
| T15 | 91-100 | C0077126 | denotes | riflusal, |
| T16 | 1524-1531 | C0004057 | denotes | spirin |
| T17 | 1166-1173 | C0004057 | denotes | spirin |
| T18 | 942-949 | C0004057 | denotes | spirin |
| T19 | 818-825 | C0004057 | denotes | spirin |
| T20 | 954-964 | C0036075 | denotes | alicylate) |
| T21 | 304-314 | C0036075 | denotes | alicylate |
| T22 | 79-89 | C0036075 | denotes | alicylate, |
| T23 | 315-325 | C0243072 | denotes | erivatives |
| T24 | 64-75 | C0243072 | denotes | erivatives |
| T25 | 1001-1011 | C0021469 | denotes | nhibition |
| T26 | 1-11 | C0021469 | denotes | nhibition |
| T27 | 1676-1686 | C0870883 | denotes | etabolite |
| T28 | 402-412 | C0870883 | denotes | etabolite |
| T29 | 123-133 | C0870883 | denotes | etabolite, |
| T30 | 1848-1858 | C0185117 | denotes | xpression |
| T31 | 1695-1705 | C0185117 | denotes | xpression |
| T32 | 1324-1334 | C0185117 | denotes | xpression. |
| T33 | 1029-1039 | C0185117 | denotes | xpression |
| T34 | 32-42 | C0185117 | denotes | xpression |
| T35 | 1842-1847 | C1367485 | denotes | OX-2 |
| T36 | 1591-1596 | C1367485 | denotes | OX-2 |
| T37 | 1015-1020 | C1367485 | denotes | OX-2 |
| T38 | 845-850 | C1367485 | denotes | OX-2 |
| T39 | 687-692 | C1367485 | denotes | OX-2- |
| T40 | 239-254 | C1367485 | denotes | yclooxygenase-2 |
| T41 | 15-31 | C1367485 | denotes | yclooxygenase-2 |
| T42 | 1536-1553 | C0037549 | denotes | odium salicylate. |
| T43 | 1749-1753 | C0012472 | denotes | GE2 |
| T44 | 1198-1202 | C0012472 | denotes | GE2 |
| T45 | 702-717 | C0012472 | denotes | rostaglandin E2 |
| T46 | 1054-1059 | C0086418 | denotes | uman |
| T47 | 608-613 | C0086418 | denotes | uman |
| T48 | 1779-1782 | C0001128 | denotes | TB |
| T49 | 1687-1690 | C0001128 | denotes | TB |
| T50 | 1408-1411 | C0001128 | denotes | TB |
| T51 | 911-914 | C0001128 | denotes | TB |
| T52 | 645-648 | C0001128 | denotes | TB, |
| T53 | 448-452 | C0001128 | denotes | cid |
| T54 | 1123-1126 | C0034721 | denotes | at |
| T55 | 1650-1654 | C0085732 | denotes | ble |
| T56 | 1397-1404 | C0085732 | denotes | bility |
| T57 | 1779-1782 | C0700307 | denotes | TB |
| T58 | 1687-1690 | C0700307 | denotes | TB |
| T59 | 1408-1411 | C0700307 | denotes | TB |
| T60 | 911-914 | C0700307 | denotes | TB |
| T61 | 645-648 | C0700307 | denotes | TB, |
| T62 | 415-422 | C0700307 | denotes | ydroxy- |
| T63 | 1318-1323 | C0033551 | denotes | OX-2 |
| T64 | 1932-1937 | C0017337 | denotes | enes |
| T65 | 1084-1095 | C0700325 | denotes | bservation |
| T66 | 1127-1130 | C0001861 | denotes | ir |
| T67 | 614-619 | C0005768 | denotes | lood, |
| T68 | 579-597 | C0023810 | denotes | ipopolysaccharide- |
| T69 | 1188-1197 | C0311403 | denotes | nhibited |
| T70 | 826-835 | C0311403 | denotes | nhibited |
| T71 | 677-686 | C0311403 | denotes | nhibited |
| T72 | 1576-1586 | C3463820 | denotes | nhibiting |
| T73 | 1713-1719 | C0014442 | denotes | nzyme, |
| T74 | 851-857 | C0014442 | denotes | nzyme. |
| T75 | 1889-1894 | C0036658 | denotes | ense, |
| T76 | 1318-1323 | C1565860 | denotes | OX-2 |
| T77 | 1658-1663 | C2828370 | denotes | lock |
| T78 | 1429-1434 | C2828370 | denotes | lock |
| T79 | 216-221 | C2828370 | denotes | lock |
| T80 | 1749-1753 | C3539520 | denotes | GE2 |
| T81 | 1198-1202 | C3539520 | denotes | GE2 |
| T82 | 716-717 | C3539520 | denotes | 2 |
| T83 | 1981-1990 | C0851285 | denotes | egulated. |
| T84 | 738-742 | C0600495 | denotes | C50 |
| T85 | 1457-1477 | C0040648 | denotes | ranscription factor |
| T86 | 1198-1213 | C1514503 | denotes | GE2 production |
| T87 | 1203-1213 | C0033268 | denotes | roduction |
| T88 | 726-736 | C0033268 | denotes | roduction |
| T89 | 1439-1449 | C1879547 | denotes | ctivation |
| T90 | 598-607 | C1879547 | denotes | ctivated |
| T91 | 1266-1270 | C0205171 | denotes | nly |
| T92 | 799-803 | C0205171 | denotes | nly |
| T93 | 1609-1620 | C0302350 | denotes | herapeutic |
| T94 | 180-191 | C0302350 | denotes | herapeutic |
| T95 | 1351-1359 | C0004927 | denotes | ehavior |
| T96 | 1289-1296 | C0003062 | denotes | nimals |
| T97 | 1754-1763 | C0220781 | denotes | ynthesis. |
| T98 | 1787-1791 | C0015264 | denotes | xert |
| T99 | 1100-1106 | C1517331 | denotes | urther |
| T100 | 1143-1150 | C1515655 | denotes | n vivo, |
| T101 | 1862-1869 | C1314939 | denotes | nvolved |
| T102 | 552-559 | C1441672 | denotes | bserved |
| T103 | 1380-1384 | C1709471 | denotes | art, |
| T104 | 862-866 | C0392366 | denotes | est |
| T105 | 859-861 | C1883351 | denotes | o |
| T106 | 1297-1303 | C1547282 | denotes | howed |
| T107 | 1371-1376 | C0547044 | denotes | east |
| T108 | 881-892 | C1290905 | denotes | iscrepancy, |
| T109 | 1512-1518 | C0439792 | denotes | xtent |
| T110 | 1060-1077 | C0806987 | denotes | ononuclear cells. |
| T111 | 1978-1980 | C1282911 | denotes | p- |
| T112 | 1966-1973 | C2587213 | denotes | ontrol |
| T113 | 1060-1071 | C1513475 | denotes | ononuclear |
| T114 | 465-473 | C1707455 | denotes | ompared |
| T115 | 1804-1811 | C1280500 | denotes | ffects |
| T116 | 226-235 | C0205263 | denotes | nduction |
| T117 | 192-201 | C3245505 | denotes | otential |
| T118 | 1306-1314 | C0392756 | denotes | ecrease |
| T119 | 1597-1605 | C1561536 | denotes | ctivity |
| T120 | 569-578 | C0521009 | denotes | acterial |
| T121 | 1108-1117 | C0750484 | denotes | onfirmed |
| T122 | 1137-1142 | C3161035 | denotes | odel |
| T123 | 1131-1136 | C1706199 | denotes | ouch |
| T124 | 1341-1350 | C1705242 | denotes | ifferent |
| T125 | 1899-1911 | C1521733 | denotes | athological |
| T126 | 872-879 | C0750489 | denotes | pparent |
| T127 | 1834-1841 | C1515568 | denotes | e novo |
| T128 | 1505-1511 | C0205250 | denotes | igher |
| T129 | 1881-1888 | C0332464 | denotes | roader |
| T130 | 654-657 | C1518422 | denotes | ot |
| T131 | 1236-1241 | C0439272 | denotes | g/kg |
| T132 | 1043-1053 | C0205100 | denotes | eripheral |
| T133 | 836-844 | C1998793 | denotes | urified |
| T134 | 1281-1288 | C1522326 | denotes | reated |
| T135 | 282-285 | C0205448 | denotes | wo |
| T136 | 693-701 | C0127400 | denotes | ediated |
| T137 | 1749-1763 | C1157324 | denotes | GE2 synthesis. |
| T138 | 1709-1711 | C0205314 | denotes | ew |
| T139 | 205-210 | C0013227 | denotes | rugs |
| T140 | 1621-1635 | C0086045 | denotes | oncentrations, |
| T141 | 977-990 | C1446561 | denotes | oncentration- |
| T142 | 991-1000 | C0851827 | denotes | ependent |
| T143 | 1471-1477 | C1521761 | denotes | actor |
| T144 | 1815-1824 | C1522240 | denotes | rocesses |